In this study, we demonstrated that combination therapy with Ad-p53 DCs and OBP-702 markedly reduced the growth of murine CC tumor models with p53 wild-type and p53 mutant tumor cells by activating tumor-infiltrating CD8+ CTLs and CD11c+ DCs. The gene discussed is CD8A; the disease is neoplasm.